Colchicine |
Catalog No.GC13261
One-Click Copy Product Info
|
Colchicine, an orally active alkaloid, disrupts cytoskeletal function by inhibiting the polymerization of β-tubulin into microtubules, with an IC50 of 3 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 64-86-8
Sample solution is provided at 25 µL, 10mM.
Colchicine, an orally active alkaloid, disrupts cytoskeletal function by inhibiting the polymerization of β-tubulin into microtubules, with an IC50 of 3 nM. Additionally, colchicine acts as a competitive antagonist of the α3 glycine receptor (GlyR) [1]. Colchicine exhibits a broad spectrum of anti-inflammatory, immunosuppressive, and potent anti-fibrotic effects, making it effective in controlling gout and reducing the risk of cardiovascular events [2-3].
Colchicine(10 nM; 1h) prevented foam cell formation induced by ox-LDL in macrophages differentiated from human THP-1 cells[4]. Colchicine (1 nM; 24h) treatment diminished GSK-3β phosphorylation and β-catenin translocation to the nucleus in cultured human aortic SMCs exposed to PDGF-BB stimulation[5].
Colchicine (0.102 mg/kg; 12 weeks; i.g) demonstrates anti-atherosclerotic and plaque-stabilizing effects at low doses by inhibiting foam cell formation and reducing cholesterol crystal-induced inflammation[4]. Colchicine (0.1 mg/kg/d; i.p.; 2 weeks) can restrict abdominal aortic aneurysm (AAA) formation by preventing the infiltration of immune cells into the aortic wall[6]. Colchicine inhibits the activation of the NLRP3 inflammasome, thereby preventing small intestine damage induced by non-steroidal anti-inflammatory drugs (NSAIDs)[7].
References:
[1]. Muñoz-Montesino C, Burgos CF, et,al. Inhibition of the Glycine Receptor alpha 3 Function by Colchicine. Front Pharmacol. 2020 Jul 30;11:1143. doi: 10.3389/fphar.2020.01143. PMID: 32903667; PMCID: PMC7438739.
[2]. McKenzie BJ, Wechalekar MD, et,al. Colchicine for acute gout. Cochrane Database Syst Rev. 2021 Aug 26;8(8):CD006190. doi: 10.1002/14651858.CD006190.pub3. PMID: 34438469; PMCID: PMC8407279.
[3]. Zhang FS, He QZ, et,al.Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacol Sin. 2022 Sep;43(9):2173-2190. doi: 10.1038/s41401-021-00835-w. Epub 2022 Jan 19. PMID: 35046517; PMCID: PMC8767044.
[4]. Schwarz N, Fernando S, et,al. Colchicine exerts anti-atherosclerotic and -plaque-stabilizing effects targeting foam cell formation. FASEB J. 2023 Apr;37(4):e22846. doi: 10.1096/fj.202201469R. PMID: 36856983.
[5]. Chen M, Yang D, et,al. Colchicine Blocks Abdominal Aortic Aneurysm Development by Maintaining Vascular Smooth Muscle Cell Homeostasis. Int J Biol Sci. 2024 Mar 17;20(6):2092-2110. doi: 10.7150/ijbs.93544. PMID: 38617538; PMCID: PMC11008260.
[6]. Zhao Y, Shen QR, et,al. Colchicine protects against the development of experimental abdominal aortic aneurysm. Clin Sci (Lond). 2023 Oct 11;137(19):1533-1545. doi: 10.1042/CS20230499. PMID: 37748024; PMCID: PMC10550771.
[7]. Otani K, Watanabe T, et,al. Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Sci Rep. 2016 Sep 2;6:32587. doi: 10.1038/srep32587. PMID: 27585971; PMCID: PMC5009328.
| Cell experiment [1]: | |
|
Cell lines |
MDMs (Human monocyte-derived macrophages) differentiated from human THP-1 cells |
|
Preparation Method |
For studying human ORO foam cell formation, MDMs were initially treated for 1 hour with colchicine (10 nM), vinblastine (10 nM), or paclitaxel (100 nM), and subsequently exposed to ox-LDL as described previously. |
|
Reaction Conditions |
10 nM; 1h |
|
Applications |
Colchicine prevented foam cell formation induced by oxidized LDL (ox-LDL) in macrophages differentiated from human THP-1 cells. |
| Animal experiment [2]: | |
|
Animal models |
C57BL / 6J Apoe−/− mice |
|
Preparation Method |
Mice were fed an atherogenic high-cholesterol diet (HCD) containing 0.15% cholesterol and 21% fat for 16 weeks, starting at 8 weeks of age. In the fourth week, they were randomly assigned to receive either phosphate-buffered saline (PBS) or colchicine at 0.102 mg/kg via daily oral gavage for 12 weeks. |
|
Dosage form |
0.102 mg/kg; 12weeks; i.g |
|
Applications |
Colchicine reduces lipidic atherosclerotic plaques in mouse aorta. |
|
References: |
|
| Cas No. | 64-86-8 | SDF | |
| Chemical Name | N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide | ||
| Canonical SMILES | CC(=O)NC1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC | ||
| Formula | C22H25NO6 | M.Wt | 399.44 |
| Solubility | ≥ 19.972 mg/mL in DMSO, ≥ 50.8 mg/mL in EtOH with gentle warming, ≥ 45.5 mg/mL in Water with gentle warming | Storage | Store at 4°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5035 mL | 12.5175 mL | 25.035 mL |
| 5 mM | 500.7 μL | 2.5035 mL | 5.007 mL |
| 10 mM | 250.4 μL | 1.2518 mL | 2.5035 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)